Total patients (n=14) Total patients (n=14)
Number of VDC-ICE cycles completed/patient Number of VDC-ICE cycles completed/patient
<8 cycles <8 cycles 5 (36) 5 (36)
8 cycles 8 cycles
9 (64)
9 (64)
Additional concurrent regimen administered Additional concurrent regimen administered
Yes Yes
3 (21)
3 (21)
No No
11 (79)
11 (79)
Planned chemotherapy dose per cycle, median (range) Planned chemotherapy dose per cycle, median (range)
cyclophosphamide (mg/m2) cyclophosphamide (mg/m2)
1500 (1200-2100)
1500 (1200-2100)
doxorubicin (mg/m2) doxorubicin (mg/m2)
45 (45-75)
45 (45-75)
ifosfamide (gm/m2) ifosfamide (gm/m2)
6 (6-6)
6 (6-6)
vincristine (mg/m2) vincristine (mg/m2)
4.5 (2-4.5)
4.5 (2-4.5)
carboplatin (AUC target, mg/ml-min) carboplatin (AUC target, mg/ml-min)
6 (6-6)
6 (6-6)
etoposide (mg/m2) etoposide (mg/m2)
300 (300-300)
300 (300-300)
Received dexrazoxane Received dexrazoxane 14 (100) 14 (100)
Received growth factor after every cycle Received growth factor after every cycle 14 (100) 14 (100)
Cumulative chemotherapy dose (for patients who completed treatment), median (range) Cumulative chemotherapy dose (for patients who completed treatment), median (range)
cyclophosphamide (mg/m2) cyclophosphamide (mg/m2)
6000 (4800-8400)
6000 (4800-8400)
ifosfamide (g/m2) ifosfamide (g/m2)
24 (21-24)
24 (21-24)
doxorubicin dose (mg/m2) doxorubicin dose (mg/m2)
270 (135-450)
270 (135-450)
Received radiation Received radiation 9 (64) 9 (64)
Primary site, n (%) Primary site, n (%) 9 (64) 9 (64)
Flank Flank 2 (22) 2 (22)
Other Other 7 (78) 7 (78)
Metastatic site, n (%) Metastatic site, n (%) 3 (21) 3 (21)
Lung Lung 2 (67) 2 (67)
Bone Bone 1 (33) 1 (33)
Timing of radiation, n (%) Timing of radiation, n (%)
Pre-chemotherapy Pre-chemotherapy
1 (11)
1 (11)
During chemotherapy During chemotherapy
7 (78)
7 (78)
Post-chemotherapy Post-chemotherapy
1 (11)
1 (11)
Age at radiation (years), median (range) Age at radiation (years), median (range) 3.4 (1.6-11.2) 3.4 (1.6-11.2)
Underwent surgical resection, n (%) Underwent surgical resection, n (%) 10 (71) 10 (71)
Complete resection Complete resection
7 (54)
7 (54)
Gross resection Gross resection
2 (15)
2 (15)
Unknown Unknown
1 (8)
1 (8)
Timing of surgical resection, n (%) Timing of surgical resection, n (%)
Upfront Upfront
6 (60)
6 (60)
After neoadjuvant chemotherapy After neoadjuvant chemotherapy
4 (40)
4 (40)
Age at surgery (years), median (range) Age at surgery (years), median (range) 1.7 (0.3-9.3) 1.7 (0.3-9.3)
Biopsy only, n (%) Biopsy only, n (%) 4 (31) 4 (31)